Sunesis Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on BCI Minerals (BCI), Seneca Global Income and Growth Investment Trust (SIGT), Sunesis...
182 Views
Sunesis Pharmaceuticals - A shift of gears
Sunesis’s task in realigning the company towards its new lead asset SNS-510 is twofold. First, it is examining the precise direction it intends to...
89 Views
Sunesis Pharmaceuticals - Vecabrutinib not to progress, SNS-510 elevated
Sunesis announced on 23 June that it would not be advancing vecabrutinib to the Phase II portion of its Phase Ib/II study following the results...
161 Views
Sunesis Pharmaceuticals - 400mg data similar to previous cohort
On 18 March, Sunesis released the first assessments of the 400mg cohort in its ongoing dosing study of vecabrutinib for B-cell malignancies. Two...
606 Views
Sunesis Pharmaceuticals - Sunesis 110320
Sunesis provided an update on its ongoing dosing study of vecabrutinib on its 2019 earning conference call: the first response assessment for the...
641 Views